Literature DB >> 20362993

Association between metabolic syndrome or its components and asymptomatic cardiovascular disease in the RIVANA-study.

M J Guembe1, E Toledo, J Barba, E Martínez-Vila, P González-Diego, P Irimia, J Díez, J J Viñes.   

Abstract

OBJECTIVE: To assess the association between the metabolic syndrome (MetSd) and asymptomatic cardiovascular disease and determine if the MetSd or its single risk factors perform better in discriminating prevalent asymptomatic cardiovascular disease.
METHODS: A total of 880 community-dwelling subjects (423 with and 457 without MetSd according to ATPIII) underwent a physical examination, an echocardiography and an ultrasound examination of carotid arteries and blood and urine samples were collected. Associations between the subclinical organ damage markers and the MetSd were addressed with non-conditional logistic regression. AUCs of ROCs were used to compare the models' ability to discriminate asymptomatic cardiovascular disease.
RESULTS: The MetSd was independently associated with carotid subclinical atherosclerosis, increased left ventricular mass index and cardiac dysfunction. The MetSd did not discriminate prevalent increased carotid intima-media thickness better than abdominal obesity and impaired fasting glucose [AUC=0.75 (95% CI: 0.71-0.78) and 0.75 (0.71-0.79), respectively; p=0.55]. The MetSd performed worse than abdominal obesity in discriminating increased left ventricular mass index among males younger than 65 years [AUC=0.66 (95% CI: 0.62-0.69) and 0.69 (0.66-0.73), respectively; p=0.02]. No differences between the ability of MetSd or its components in discriminating increased left ventricular mass index were observed among older men or women. The discrimination ability for microalbuminuria for the MetSd or impaired fasting glucose was not statistically different [AUC=0.67 (95% CI: 0.60-0.74) and 0.69 (0.62-0.76), respectively; p=0.18].
CONCLUSION: This study supports the association between the MetSd and asymptomatic cardiovascular disease. The construct of the MetSd might not be better than its single components in addressing cardiovascular risk. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20362993     DOI: 10.1016/j.atherosclerosis.2010.03.004

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

Review 1.  Hypogonadism and metabolic syndrome.

Authors:  G Corona; G Rastrelli; A Morelli; L Vignozzi; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2011-06-27       Impact factor: 4.256

2.  Metabolic syndrome is a predictor of decreased renal function among community-dwelling middle-aged and elderly Japanese.

Authors:  Ryuichi Kawamoto; Taichi Akase; Daisuke Ninomiya; Teru Kumagi; Asuka Kikuchi
Journal:  Int Urol Nephrol       Date:  2019-10-22       Impact factor: 2.370

3.  The effectiveness of IDF and ATP-III in identifying metabolic syndrome and the usefulness of these tools for health-promotion in older Taiwanese.

Authors:  M M Chen; A C Tsai
Journal:  J Nutr Health Aging       Date:  2013-04       Impact factor: 4.075

4.  Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study.

Authors:  Dhayana Dallmeier; Martin G Larson; Ramachandran S Vasan; John F Keaney; Joao D Fontes; James B Meigs; Caroline S Fox; Emelia J Benjamin
Journal:  Diabetol Metab Syndr       Date:  2012-06-20       Impact factor: 3.320

5.  Influence of age on the prevalence and components of the metabolic syndrome and the association with cardiovascular disease.

Authors:  Marion C Devers; Stewart Campbell; David Simmons
Journal:  BMJ Open Diabetes Res Care       Date:  2016-04-25

6.  Metabolic Syndrome and Chronic Renal Disease.

Authors:  Vaia D Raikou; Sotiris Gavriil
Journal:  Diseases       Date:  2018-01-24

7.  Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort.

Authors:  María J Guembe; Cesar I Fernandez-Lazaro; Carmen Sayon-Orea; Estefanía Toledo; Conchi Moreno-Iribas
Journal:  Cardiovasc Diabetol       Date:  2020-11-22       Impact factor: 9.951

8.  Enhanced prediction of renal function decline by replacing waist circumference with "A Body Shape Index (ABSI)" in diagnosing metabolic syndrome: a retrospective cohort study in Japan.

Authors:  Daiji Nagayama; Kentaro Fujishiro; Shinichi Tsuda; Yasuhiro Watanabe; Takashi Yamaguchi; Kenji Suzuki; Atsuhito Saiki; Kohji Shirai
Journal:  Int J Obes (Lond)       Date:  2021-11-25       Impact factor: 5.095

Review 9.  Various Obesity Indices and Arterial Function Evaluated with CAVI - Is Waist Circumference Adequate to Define Metabolic Syndrome?

Authors:  Daiji Nagayama; Tomonori Sugiura; Su-Yeon Choi; Kohji Shirai
Journal:  Vasc Health Risk Manag       Date:  2022-09-12

10.  Impaired Fasting Glucose Is the Major Determinant of the 20-Year Mortality Risk Associated With Metabolic Syndrome in Nondiabetic Patients With Stable Coronary Artery Disease.

Authors:  Arwa Younis; Ronen Goldkorn; Ilan Goldenberg; Diklah Geva; Boaz Tzur; Anna Mazu; Anan Younis; Zvi Fisman; Alexander Tannenbaum; Robert Klempfner
Journal:  J Am Heart Assoc       Date:  2017-10-27       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.